Breaking

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Advertisement

Biopharma

Clinical evidence, research, and medical intelligence in Biopharma.

Advertisement

Biopharma · MedCity

Argenx buys Unnatural Products to expand into oral peptide drugs

Argenx is buying Unnatural Products for $550 million upfront to add macrocyclic peptide discovery and widen its immunology pipeline beyond antibodies.

By Dr. A. Nikhil Krishnan, MBBS · 3 days ago · 5 min read

Biopharma·MedCity

City Therapeutics IPO Raises $200M for RNAi Drugs Beyond the Liver

City Therapeutics raised $200 million in an upsized IPO to advance RNAi therapies for clotting, eye disease, and…

Biopharma·MedCity

Ultragenyx sells rare disease vouchers for $413M to fund pipeline

Ultragenyx sold two priority review vouchers for $413 million, strengthening its cash position after rare disease gene therapy…

Biopharma

Clinical evidence, research, and medical intelligence in Biopharma.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.

Advertisement

Most Read

Medicine World Foundation Alerts

Daily Clinical Dispatch

Receive peer-screened summaries across 17 clinical specialties delivered to your inbox every morning.

Trending Topics Clinical Keywords

#GLP-1 #Lecanemab #CAR-T #SepsisBundle #Semaglutide #SGLT2 #LongCOVID #AntibioticStewardship #AIDiagnostics #Statins

Advertisement

Advertisement